Connect with us

Technology

3D Printing Medical Devices Market size is set to grow by USD 7.07 billion from 2024-2028, Increased demand for personalized or customized medical devices boost the market, Technavio

Published

on

NEW YORK, July 30, 2024 /PRNewswire/ — The global 3D printing medical devices market size is estimated to grow by USD 7.07 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 25.2%  during the forecast period. Increased demand for personalized or customized medical devices is driving market growth, with a trend towards rising focus on the research for the use of 3D printing process to manufacture living organs and cell structures. However, high initial setup cost of 3d printing facility  poses a challenge. Key market players include 3D Systems Corp., Anatomics Pty Ltd., Autodesk Inc., Biomerics LLC, Boston Scientific Corp., Desktop Metal Inc., EOS GmbH, Exail Technologies, Formlabs Inc., General Electric Co., INTAMSYS TECHNOLOGY CO. LTD., MATERIALISE NV, Mecuris GmbH, Medtronic Plc, Organovo Holdings Inc., Qualtech Consulting Corp., Renishaw Plc, Schultheiss GmbH, SLM Solutions Group AG, and Stratasys Ltd..

Get a detailed analysis on regions, market segments, customer landscape, and companies- View the snapshot of this report

3D Printing Medical Devices Market Scope

Report Coverage

Details

Base year

2023

Historic period

2018 – 2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 25.2%

Market growth 2024-2028

USD 7079.6 million

Market structure

Fragmented

YoY growth 2022-2023 (%)

19.78

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 40%

Key countries

US, Germany, UK, Japan, and China

Key companies profiled

3D Systems Corp., Anatomics Pty Ltd., Autodesk Inc., Biomerics LLC, Boston Scientific Corp., Desktop Metal Inc., EOS GmbH, Exail Technologies, Formlabs Inc., General Electric Co., INTAMSYS TECHNOLOGY CO. LTD., MATERIALISE NV, Mecuris GmbH, Medtronic Plc, Organovo Holdings Inc., Qualtech Consulting Corp., Renishaw Plc, Schultheiss GmbH, SLM Solutions Group AG, and Stratasys Ltd.

Market Driver

The 3D printing of medical devices, specifically in the field of bioprinting, represents a significant advancement in healthcare technology. This process involves the precise layering of cells, biologic scaffolds, and growth factors to create bioidentical tissue, such as stem cells, skin grafts, and bone and cartilage. Unlike traditional 3D printers that use plastic or metals as raw materials, 3D bioprinters utilize a computer-guided pipette to layer living cells, referred to as bioink, to create artificial living tissues. One of the most promising applications of 3D bioprinting is in organ replacement. This technology holds the potential to address the organ donor shortage and reduce rejections by creating organs that better meet the requirements of the body. For instance, 3D printed bone features a micropore surface that allows osteocytes to adhere, join, and heal better than traditional metal implants. ORGANOVO, a biotechnology company, is pioneering the use of 3D bioprinting to develop in vivo liver tissues for treating rare, life-threatening diseases. Their product, the ExVive 3D Bioprinted Human Liver Tissues, can be used for drug exposure and metabolism studies, offering a valuable alternative to organ transplantation. Allevi and SHIBUYA are among the companies leading the way in 3D bioprinting technology. Allevi introduced the first desktop 3D bioprinter capable of printing living tissues using human cells, while SHIBUYA’s 3D bioprinter is the first cell culture system for building complex cell-based structures. The potential of 3D bioprinting is driving increased R&D efforts in developing devices for this technology. As technological advances continue, 3D printing medical devices are expected to see widespread adoption, fueling the growth of the global 3D printing medical devices market. 

The 3D Printing Medical Devices market is experiencing significant growth due to its ability to produce customized, patient-specific solutions for various medical applications. Stereolithography (SLA) and digital light processing are popular 3D printing technologies used in creating prosthetics implants, orthopedic implants, and wearable medical devices. Dentistry and orthodontics also benefit from 3D printing, with applications including dentures, bone scaffolds, and hearing aids. Tissue-engineered products, remote patient monitoring, telemedicine, and vital signs monitoring are other areas where 3D printing is making an impact. Complex medical procedures, such as implantable and non-implantable medical devices, drug testing, and organ and tissue production, are also being revolutionized by this technology. Computer-aided manufacturing and design, diagnostic centers, medical institutions, and 3D printing laboratories are embracing 3D printing to provide personalized solutions. Laser beam technology, minimally invasive surgery, and surgical equipment are other areas where 3D printing is making a difference. Patient CAD images are used to create patient-specific models and customized implants, including cranial implants for neurosurgery and human skull repairs. Overall, 3D printing is transforming the medical industry by enabling the production of customized, high-quality medical devices in a layer-wise manner. 

Discover 360° analysis of this market. For complete information, schedule your consultation – Book Here!

Market Challenges

The 3D printing medical devices market faces significant challenges due to high capital costs. Equipment for 3D printing or outsourced print service contracts, advanced software for post-processing, and proprietary raw materials contribute to these costs. Desktop FDM or SLA machines cost less than USD5,000, but high-end additive manufacturing printers range from USD200,000 to USD850,000 or even millions. Skilled personnel and training are also necessary, adding to the expenses. A clinical 3D printing lab requires ancillary staff for printing. Production time, ranging from hours to days, limits its use in mass manufacturing. These factors hinder the widespread adoption of 3D printers, potentially impacting the growth of the market negatively.The 3D printing medical devices market is experiencing significant growth due to the advantages it offers in creating customized solutions for various medical needs. However, there are challenges that need to be addressed. For physicians, the use of 3D-printed medical devices in elective surgical procedures requires careful consideration for complex prosthetic limbs and brain designs. Surgeons prefer titanium alloys for surgical tools, but cancer patients benefit from biocompatible materials as drug contact materials. Hearing aid manufacturers are exploring 3D-printed hearing aid devices using biocompatible materials for personalized solutions. CAD/CAM technology and desktop printers are revolutionizing dental clinics and hospitals, providing dental restoration, surgical planning, and personalized prosthetics. Orthopedic prosthetics and surgical instruments also benefit from 3D printing, improving surgical outcomes, operation time, and reducing post-surgical complications. Mechanical protection for tissues and organs is a promising area for 3D printing, with potential applications in organ transplantation and living cells using biomaterials. However, biosafety concerns and ethical issues surrounding the use of human cells and tissues need to be addressed by regulatory bodies like the Human Tissue Authority. Photopolymerization and Medical device manufacturers are using rapid prototyping to innovate, while healthcare professionals embrace the technology for prosthetics, surgical instruments, personalized prosthetics, orthotics, surgeon comfort, and fatigue prevention.

For more insights on driver and challenges – Request a sample report!

Segment Overview 

This 3d printing medical devices market report extensively covers market segmentation by  

Application 1.1 Orthopedic and spinal1.2 Dental1.3 Hearing aids1.4 OthersEnd-user 2.1 Hospitals and clinics2.2 Academic institutes2.3 Pharma and biotech companies2.4 OthersGeography 3.1 North America3.2 Europe3.3 Asia3.4 Rest of World (ROW)

1.1 Orthopedic and spinal-  The 3D printing medical devices market encompasses the production of orthopedic and spinal implants using 3D printing technology. This technology enables the fabrication of standard-sized implants, patient-matched implants, and custom implants for individuals with deformities. Hospitals and ambulatory surgery centers are major end-users, as 3D printing allows for the creation of complex structures and individualized implants. Orthopedic and spinal applications dominate the market due to the rising prevalence of related disorders, increasing demand for personalized implants, and the need for advanced surfaces and structures. The technology’s ability to manufacture lattice structures and porous surfaces promotes bone ingrowth and improves implant stability. Titanium implants, commonly used in orthopedics, benefit from 3D printing’s ability to create greater porosity, enhancing bony ingrowth and improving implant stability. In the field of prosthetics, 3D printing significantly reduces manufacturing time and costs while maintaining functionality. The technology’s affordability makes it particularly suitable for children who quickly outgrow their prosthetic limbs. Vendors are increasing investments in R&D to develop advanced orthopedic and spinal implants, further fueling market growth. Key factors driving the market include the aging population, increasing prevalence of orthopedic and spinal disorders, and the demand for customized implants. These factors are expected to propel the growth of the global 3D printing medical devices market during the forecast period.

For more information on market segmentation with geographical analysis including forecast (2024-2028) and historic data (2017-2021) – Download a Sample Report

Research Analysis

The 3D printing medical devices market is revolutionizing the healthcare industry by enabling the production of customized medical products in a layer-wise manner using CAD images. This technology allows for the creation of patient-specific products, including implants, hearing aids, bone scaffolds, surgical equipment, and more. The process begins with the creation of patient CAD images, which are then used to manufacture standard implants or personalized prosthetics, surgical instruments, and orthotics. The benefits of 3D printing in medical devices extend beyond patient comfort, as it also allows for the production of implantable and non-implantable medical devices using biomaterials, as well as drug testing and potential applications in organ transplantation and tissue engineering. Rapid prototyping and computer-aided manufacturing are key technologies driving the growth of this market, with healthcare professionals and medical device manufacturers embracing the technology to improve patient outcomes and surgical procedures.

Market Research Overview

The 3D printing medical devices market is revolutionizing the healthcare industry by enabling the production of customized medical products in a layer-wise manner using CAD images. This technology allows for the creation of patient-specific products such as implants, hearing aids, bone scaffolds, surgical equipment, and more. The use of patient CAD images ensures a perfect fit and optimal surgical outcomes, reducing operation time and post-surgical complications. 3D printing technology is being applied in various medical fields, including neurosurgery, orthopedics, and dentistry. For instance, it is used to create cranial implants, patient-specific models, and surgical tools for complex procedures. The use of biocompatible materials, such as titanium alloys and photopolymers, ensures the safety and effectiveness of 3D-printed medical devices. The market for 3D-printed medical devices is vast and diverse, encompassing elective surgical procedures, complex prosthetic limbs, brain designs, surgical instruments, and more. The technology is also being used in tissue engineering and organ transplantation, with the potential to print living cells and biomaterials. However, the use of 3D printing in medicine raises biosafety concerns and ethical issues, particularly with regard to the Human Tissue Authority and patient privacy. Medical device manufacturers are working to address these challenges through the use of CAD/CAM technology, rapid prototyping, and collaboration with healthcare professionals. The market for 3D-printed medical devices includes hearing aid manufacturers, dental clinics, hospitals, and surgical planning centers. The technology is also being used to create implantable and non-implantable medical devices, wearable medical devices, and diagnostic tools. The potential applications of 3D printing in medicine are vast, from surgical planning and dental restoration to remote patient monitoring and telemedicine. The future of medicine is undoubtedly 3D printed.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

ApplicationOrthopedic And SpinalDentalHearing AidsOthersEnd-userHospitals And ClinicsAcademic InstitutesPharma And Biotech CompaniesOthersGeographyNorth AmericaEuropeAsiaRest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/3d-printing-medical-devices-market-size-is-set-to-grow-by-usd-7-07-billion-from-2024-2028–increased-demand-for-personalized-or-customized-medical-devices-boost-the-market-technavio-302209578.html

SOURCE Infiniti Research, Inc.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Pillsbury Notice of Data Breach

Published

on

By

NEW YORK, July 18, 2026 /PRNewswire/ — Pillsbury Winthrop Shaw Pittman LLP (“Pillsbury”) was among many law firms targeted by sophisticated social engineering attempts in an incident last year. While the firm quickly detected and blocked the activity, an unauthorized actor was able to access some of the firm’s documents during a short window of time. Pillsbury notified any impacted clients last year and undertook a detailed process to review the accessed documents for personal information. Pillsbury then began notifying individuals whose personal information was affected. That process is now complete, and today, Pillsbury is publishing substitute notice as a final step.

For more information, please visit the substitute notice on our website at https://www.pillsburylaw.com/en/breach-notice.html

View original content to download multimedia:https://www.prnewswire.com/news-releases/pillsbury-notice-of-data-breach-302828892.html

SOURCE Pillsbury Winthrop Shaw Pittman LLP

Continue Reading

Technology

From Remote Racing to Embodied AI: Fibocom and Intedigo Bring 5G Bidirectional Data Transmission into Real-World Applications

Published

on

By

SHANGHAI, July 18, 2026 /PRNewswire/ — From July 17 to 20, Fibocom and Intedigo will jointly present a cross-regional, beyond-visual-line-of-sight (BVLOS) teleoperation demonstration at Booth H3-C408 during the World Artificial Intelligence Conference (WAIC) 2026. Visitors will be able to enter a remote driving cockpit and control a real race car located at HURA PARK in Jiading, Shanghai, steering, accelerating, and braking in real time while experiencing how 5G connectivity enables remote operation.

More than an immersive driving experience, the demonstration provides a live validation of 5G bidirectional data transmission for embodied AI teleoperation. The vehicle continuously sends live track video, vehicle status, and operating data to the remote cockpit, while control commands are transmitted back to the vehicle, creating a closed-loop teleoperation system. Stable, low-latency, and highly reliable connectivity is essential for high-dynamic maneuvers such as high-speed cornering, precision braking, and continuous lane changes.

Developed by Intedigo, the remote driving system connects a real race car with an immersive remote driving cockpit. It supports 1080p@60Hz video transmission, glass-to-glass (G2G) video latency of less than 80 ms, and control latency of less than 10 ms. The demanding racing environment magnifies differences in video continuity and control responsiveness, making communications performance directly perceptible, measurable, and verifiable.

At the joint demonstration, Fibocom’s FM160 5G module provides cellular connectivity for the system. Powered by the Qualcomm Snapdragon™ X62 5G Modem-RF System, the FM160 supports SA and NSA network architectures as well as 3GPP Release 16. On the downlink, it supports NR Carrier Aggregation (NR CA) with bandwidth of up to 120 MHz, delivering peak speeds of up to 3.5 Gbps in NSA mode and 2.5 Gbps in SA mode. On the uplink, it supports UL MIMO and delivers peak speeds of up to 900 Mbps in SA mode. These capabilities support the continuous transmission of HD video and vehicle status data, along with reliable delivery of control commands.

As embodied AI moves into factories, data centers, logistics operations, and industrial parks, robots are becoming increasingly capable of performing tasks autonomously. Yet complex environments, unexpected events, and edge cases still require Human-in-the-Loop (HITL) remote intervention to help ensure safe and reliable operation.

Daniel Liu, CEO of Intedigo, said:

“5G represents the pinnacle of human communications and the starting point of machine communications. In the past, communications connected people to people; in the future, they will connect people to robots and robots to robots. Remote racing is simply the easiest entry point for people to understand this concept. What we are truly validating is a communications system capable of supporting remote collaboration for embodied AI. HURA makes low-latency remote driving a tangible experience, while RoBOX extends this capability to robots and a broader range of intelligent terminals. Together with Fibocom, we hope to enable more machines to receive remote assistance whenever needed while remaining continuously connected and operating reliably.”

Simon Tao, VP of Wireless Solutions Business Group and General Manager of MBB BU at Fibocom, said:

“As embodied AI enters real-world industrial environments, reliable connectivity will become the foundation for telemetry feedback, remote control and operational management. Fibocom’s 5G solutions, represented by FM160, provide the cellular connectivity required for continuous on-site data transmission and reliable control command delivery. Fibocom will continue collaborating with ecosystem partners such as Intedigo to bring cellular connectivity to more robots, autonomous machines and mobile intelligent terminals, enabling embodied AI systems to stay continuously connected and respond reliably in real-world applications.”

From remote race cars to robots, unmanned equipment, and mobile intelligent terminals, 5G is evolving from connecting people to connecting machines. This joint demonstration makes the capabilities of 5G bidirectional data transmission directly perceptible, experiential, and verifiable, helping pave the way for embodied AI to scale across real-world applications.
 

About Fibocom

Fibocom, founded in 1999, is China’s first wireless communication module company listed on both the A-share and H-share markets (300638.SZ, 0638.HK). As a global leading provider of wireless communication modules and AI solutions, Fibocom leverages wireless communication and artificial intelligence as its core technologies to provide integrated hardware and software solutions that empower industry applications. These solutions accelerate the transformation from “Connect Everything” to “Intelligent Connectivity” across diverse industries.

Fibocom’s one-stop solutions encompass cellular communication, AI, automotive, and GNSS modules, as well as AI toolchains, supporting industry-side and mainstream large model integration, and providing AI Agent, global connectivity, and cloud services, driving the digital intelligence upgrades in industries such as robotics, consumer electronics, low-altitude economy, intelligent transportation, smart retail, and smart energy.

View original content to download multimedia:https://www.prnewswire.com/news-releases/from-remote-racing-to-embodied-ai-fibocom-and-intedigo-bring-5g-bidirectional-data-transmission-into-real-world-applications-302828996.html

SOURCE Fibocom Wireless Inc.

Continue Reading

Technology

DR. PHONE FIX ANNOUNCES SECOND TRANCHE CLOSING OF NON-BROKERED CONVERTIBLE DEBENTURE UNIT FINANCING

Published

on

By

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

EDMONTON, AB, July 18, 2026 /CNW/ — Dr. Phone Fix Canada Corporation (“Dr. Phone Fix” or the “Company”) (TSXV: DPF) is pleased to announce that, further to its news release dated May 19, 2026 and June 24, 2026 (the “Prior News Releases”), it has closed the second tranche of its non-brokered private placement (the “Offering”) of convertible debenture units of the Company (each, a “Unit”). The Company issued 726 Units, at a price of $1,000 per Unit, for aggregate gross proceeds of $726,000. Each Unit is comprised of (i) one $1,000 principal amount unsecured convertible debenture of the Company (a “Convertible Debenture”) and (ii) 3,125 common share (“Common Share”) purchase warrants of the Company (each, a “Warrant”). Additional detail on the Offering, including terms of the Convertible Debentures and Warrants, is set out in the Prior News Releases.

In connection with the Offering, the Company paid a finder’s fee consisting of an aggregate cash fee of $50,820 and issued an aggregate of 317,625 common share purchase warrants of the Company (each, a “Finder’s Warrant”) to certain qualified arm’s length parties. Each Finder’s Warrant is exercisable to acquire one Common Share of the Company at an exercise price of $0.22 prior to the date that is 24 months from the date of issuance.

All securities issued pursuant to the Offering, including any Common Shares issuable upon conversion of the Convertible Debentures or exercise of the Warrants and Finder’s Warrants, are subject to a statutory hold period of four months and one day from the closing of the Offering, in accordance with applicable securities laws and TSX Venture Exchange (the “TSXV”) policies. 

The Offering remains subject to final acceptance of the TSXV.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described in this news release in the United States. Such securities have not been, and will not be, registered under the U.S. Securities Act, or any state securities laws, and, accordingly, may not be offered or sold within the United States, or to or for the account or benefit of persons in the United States or “U.S. Persons”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from such registration requirements.

About Dr. Phone Fix

Dr. Phone Fix is a national, award-winning, eco-friendly, and customer-centric leader in Canada’s cell phone and electronics repair and certified pre-owned device industry. Founded in 2019, the Company now operates 44 retail locations nationwide through a standardized and scalable operating platform designed to support consistent execution across multiple markets, delivering fast, reliable, and environmentally conscious repair services alongside a curated selection of certified pre-owned devices and premium accessories. Dr. Phone Fix maintains strong partnerships with OEMs and certified suppliers, ensuring consistently high-quality standards across its national footprint. With a focus on responsible device lifecycle management, customer service, and operational discipline, Dr. Phone Fix continues to set the benchmark for device care and resale in Canada.

www.docphonefix.com

NEITHER THE TSXV NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSXV) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.

Forward-Looking Information and Cautionary Statements

Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions. Forward-looking statements in this news release include statements relating to: the final acceptance of the Offering by the TSXV; and the expected use of proceeds following the closing of the Offering. Forward-looking information in this news release is based on certain assumptions and expected future events, namely: the Company’s financial condition and development plans do not change as a result of unforeseen events; the TSXV will provide its final acceptance of the Offering; and the Company will be able to obtain the financing required in order to develop and continue its business and operations. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the Company’s inability to obtain TSXV final acceptance for the Offering; the potential failure to complete the balance of the Offering or to raise the full anticipated gross proceeds; market conditions and investor demand for the Company’s securities; the Company’s inability to deploy the proceeds as currently intended; and general economic and market conditions. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

 

SOURCE Dr. Phone Fix

Continue Reading

Trending